Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population

Sleep

Volumn 33, Issue 2, 2010, Pages 169-176

  Knudsen, Stine ^a   Jennum, Poul J ^a   Alving, Jørgen ^b   Sheikh, Søren Paludan ^c   Gammeltoft, Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH EPILEPSY CENTRE   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

HLA DQB1*0602; Hypocretin 1; ICSD 2; Narcolepsy with cataplexy; Narcolepsy without cataplexy

Indexed keywords

HLA DQB1 ANTIGEN; OREXIN A;

ADULT; ARTICLE; CATAPLEXY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE CLASSIFICATION; FEMALE; HLA TYPING; HUMAN; HYPERSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; PHENOTYPE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; SLEEP; VALIDATION PROCESS;

EID: 77649200221     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.2.169     Document Type: Article

References (40)

1. Peyron C, Faraco J, Rogers W et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
2. Thannickal TC, Moore RY, Nienhuis R et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
3. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed.: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine; 2005
4. Heier MS, Evsiukova T, Vilming S, Gjerstad MD, Schrader H, Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007;30:969-73.
5. Martinez-Rodriguez JE, Iranzo A, Casamitjana R, Graus F, Santamaria J. [Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia]. Med Clin (Barc) 2007;128:361-4.
6. Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74:1667-73.
7. Jeong JH, Hong SC, Shin YK, Han JH, Lee SP. HLA-DQB1 allele and hypocretin in Korean narcoleptics with cataplexy. J Korean Med Sci 2007;22:127-31.
8. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008;7:649-62.
9. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
10. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
11. Knudsen S, Jennum PJ, Korsholm K, Sheikh SP, Gammeltoft S, Frederiksen JL. Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis. Mult Scler 2008;14:734-8.
12. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
13. Arii J, Kanbayashi T, Tanabe Y, et al. CSF hypocretin-1 (orexin-a) levels in childhood narcolepsy and neurologic disorders. Neurology 2004;63:2440-2.
14. Baumann CR, Khatami R, Werth E, Bassetti CL. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. J Neurol Neurosurg Psychiatry 2006;77:402-4.
15. Kanbayashi T, Inoue Y, Kawanishi K. et al. CSF hypocretin measures in patients with obstructive sleep apnea. J Sleep Res 2003;12:339-41.
16. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord 2008;23:858-65.
17. Oka Y, Inoue Y, Kanbayashi T, et al. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. Sleep 2006;29:1439-43.
18. Martinez-Rodriguez JE, Sabater L, Graus F, Iranzo A, Santamaria J. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep 2007;30:27-8.
19. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-3.
20. Kubota H, Kanbayashi T, Tanabe Y et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003;26:555-7.
21. Tsukamoto H, Ishikawa T, Fujii Y, Fukumizu M, Sugai K, Kanbayashi T. Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy. Neuropediatrics 2002;33:51-2.
22. Hong SC, Leen K, park SA, et al. HLA and hypocretin studies in Korean patients with narcolepsy. Sleep 2002;25:440-4.
23. Hong SC, Lin L, Jeong JH, et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 2006;29:1429-38.
24. Arnulf I, Lin L, Zhang J, et al. CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? Sleep 2006;29:1017-24.
25. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40.
26. Nishino S, Ripley B, Overeem S, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8.
27. Overeem S, Dalmau J, Bataller L, et al. Hypocretin-1 CSF levels in anti- Ma2 associated encephalitis. Neurology 2004;62:138-40.
28. Overeem S, Verschuuren JJ, Fronczek R, et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol 2006;174:187-91.
29. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8.
30. Lin L, Mignot E. Human leukocyte antigen and narcolepsy: present status and relationship with familial history and hypocretin deficiency. In: Bassetti C, Billiard M, Mignot E,eds Narcolepsy and hypersomnia. New York: Informa Health Care, 2007: 411-26.
31. Bassetti C, Gugger M, Bischof M, et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin 1 (orexin A). Sleep Med 2003;4:7-12.
32. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130(Pt 11):2770-8.
33. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-63.
34. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 2006;60:153.
35. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10 year-old boy. J Sleep Res 2003;12:347-8.
36. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB *0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-20.
37. Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur Neurol 2004;52:73-6.
38. Nishino S, Kanbayashi T, Fujiki N, et al. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003;61:823-5.
39. Baumann CR, Bassetti CL. CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2004;62:2337.
40. Mignot E, Lin L, Finn L, et al. Correlates of sleep-onset REM periods during the multiple sleep latency test in community adults. Brain 2006;129(Pt 6):1609-23.